Amber Specialty Pharmacy Adds to Pfizer’s Limited Distribution Network for Oncology Portfolio


OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy today announced that it will begin distributing 13 Pfizer oncology products. The pharmacy’s full-service model will support oncology patients, caregivers and specialists across the country. Their Oncology Center of Excellence provides an enhanced level of care throughout a patient’s treatment journey.

The Pfizer portfolio of oncology products now supported by Amber Specialty Pharmacy includes:

Besponsa® (inotuzumab ozogamicin)

Bosulif® (bosutinib)

Braftovi® (encorafenib)

Daurismo® (glasdegib)

Ibrance® (palbociclib)

Inlyta® (axitinib)

Lorbrena® (lorlatinib)

Mektovi® (binimetinib)

Mylotarg® (gemtuzumab ozogamicin)

Sutent® (sunitinib malate)

Talzenna® (talazoparib)

Vizimpro® (dacomitinib)

Xalkori® (crizotinib)

Amber Specialty Pharmacy is authorized to ship prescription drugs to all 50 states of the United States, as well as Puerto Rico.

For more information about Amber Specialty Pharmacy services, call (888) 370-1724 or visit

About Amber Specialty Pharmacy

Amber Specialty Pharmacy, a subsidiary of Hy-Vee, Inc., is a pioneer and leader in the specialty pharmacy industry with over 23 years of experience providing specialty care to people with chronic and complex illnesses. . Amber Specialty Pharmacy has built an exceptional reputation for providing personalized support and quality clinical care to patients and families. This comprehensive care approach meets the medical, emotional, financial and administrative needs of patients across the United States. Amber Specialty Pharmacy is accredited by the Use Review Accreditation Commission (URAC) and the Healthcare Accreditation Commission (ACHC). Amber Specialty Pharmacy is headquartered in Omaha, Nebraska, with 18 additional locations in the United States and Puerto Rico. Amber Specialty Pharmacy has been named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacies.


About Author

Comments are closed.